HC Wainwright restated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a research note published on Tuesday morning, Benzinga reports. They currently have a $48.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2024 earnings at ($2.61) EPS, Q3 2024 earnings at […]